$ 13.59 -0.17 (1.24%)
Day High: 14.10
Day Low:  13.42
Volume:    520,100
1:00 PM ET on
Nov 27, 2015

Delayed ~20 min., by eSignal.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Corporate Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at

Shareholder Inquiries

Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.

Corporate Headquarters

ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600


Corporate Counsel

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA

Transfer Agent and Registrar

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Phone: (877) 830-4936
Fax: (215) 553-5402


Independent Accountants

Ernst & Young LLP
Boston, MA

You are now leaving this website. If you would like to continue, click Continue.